Navigation Links
Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations

GLP-1 Has Potential to Treat Type 2 Diabetes Using Emisphere's Eligen(R)


CEDAR KNOLLS, N.J., July 8 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced findings from a clinical study assessing the oral delivery of GLP-1 peptide safely and effectively. The study used a delivery-agent-based approach using Emisphere's Eligen(R) technology, and was conducted at University Hospital in Basel, Switzerland by Christoph Beglinger, M.D., of the Clinical Research Center, Department of Biomedicine Division of Gastroenterology, and Department of Clinical Pharmacology and Toxicology at the hospital.

Prof. Beglinger's study, conducted in 16 healthy male subjects, was designed to explore the pharmacodynamic effects of a single oral dose of GLP-1 administered 15 minutes prior to an oral glucose tolerance test.

For the study, GLP-1 was formulated as a tablet with Emisphere's delivery agent known as SNAC. This was Prof. Beglinger's second clinical study of the compound, and it confirmed his earlier results that SNAC allows for rapid oral absorption of GLP-1. Prof. Beglinger's study also showed that pharmacological levels were achieved after a 2 mg oral dose. The study demonstrated that the oral formulation of GLP-1 stimulated an early increase in fasting insulin and a decrease in fasting glucose as compared to placebo.

"An intravenous or subcutaneous application of GLP-1 is cumbersome and impractical for chronic treatment regimens. Oral application of peptides is, however, difficult as peptides have a low oral bioavailability due to their molecular size and physico-chemical characteristics," said Prof. Beglinger. "Emisphere's oral delivery approach has been developed to overcome some of these issues."

"Prof. Beglinger's study provides yet further evidence in the application of our Eligen(R) technology as a potential solution to critical hurdles in pharmaceutical development. Hopefully, its use with GLP-1 in the treatment of diabetes will improve healthcare for millions of patients," said Michael V. Novinski, President and Chief Executive Officer of Emisphere.

Emisphere's Eligen(R) technology is based on the development of small organic molecules, termed delivery agents or carriers, that interact non-covalently with macromolecules to enable their oral absorption. GLP-1 is rapidly absorbed after oral administration with SNAC. Emisphere announced on June 23, 2008 that it entered a Development and License Agreement with Novo Nordisk A/S focused on the development of oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonists.


Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its Eligen(R) Technology. Some of these molecules or compounds can only be given by injection; when combined with our technology; convenient oral versions may be safe, effective and provide significant advantages. The benefits of other compounds are limited due to poor bioavailability, slow on-set of action or variable absorption. In those cases, use of Emisphere's technology can improve the therapeutic effectiveness of the compounds. The Eligen(R) technology can be applied to the oral route of administration as well other delivery pathways. The Web site is:

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615) filed on March 17, 2008 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2008, filed on May 7, 2008.

SOURCE Emisphere Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
3. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
4. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
5. Proof of Concept Study in Second Species Demonstrates Increase in Absorption of Oral B12 Using Emisphere Technology
6. Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 Kitov Pharma ... (TASE: KTOV), a biopharmaceutical company focused on the development ... clinical conditions, today announced the closing of its previously ... ( ADSs ), each representing 20 ordinary shares of ... ADSs. The ADSs and warrants were issued in a ...
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... today announced that Chief Executive Officer Antonius Schuh, Ph.D., ... 27 th Annual Piper Jaffray Healthcare Conference. ... the New York Palace Hotel in New ... 1:30 p.m. EST. Mr. Schuh will be available for ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... Lake, IL (PRWEB) , ... November 25, 2015 , ... ... to announce a recent successful appellate decision obtained by Attorneys Francisco J. Botto and ... case Adcock v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for the ... of the benefits of Botox® in the treatment of moderate facial wrinkling, few have ... pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism (the ...
(Date:11/25/2015)... ... 2015 , ... Beddit® has launched a new Android app for ... features a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and ... created by a proprietary algorithm. Beddit analyzes the data to provide an easy to ...
(Date:11/25/2015)... , ... November 25, 2015 , ... In an ongoing ... Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its ... surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 at ...
Breaking Medicine News(10 mins):